---
title: '【论文复现】沪深300月调多头13%'
source: 'https://www.youtube.com/watch?v=LZIGRYqGXNA'
video_id: 'LZIGRYqGXNA'
date: 2026-09-15
duration_sec: 347
channel: '量化Quantgirl'
---

# 【论文复现】沪深300月调多头13%

> Source: [【论文复现】沪深300月调多头13%](https://www.youtube.com/watch?v=LZIGRYqGXNA)

## Summary

This video presents a backtest of the ABNR (overnight reversal) signal on the CSI 300 index, adapted from a US equity study. The main long-only strategy—buying the top decile of ABNR each month—delivered 12.9% annualized with a downside deviation of 0.80, beating the index's 2.5%. However, the long-short version failed, and the study emphasizes survivorship bias and short sample windows as key limitations.

### Key Points

- **Main Strategy and Performance** [00:43] — The main tradable strategy is a long-only CSI 300 high-ABNR portfolio: monthly buy top decile, equal-weight, hold to next month-end. Long-window cumulative return 52.7%, annualized 12.9%, downside deviation 0.80, vs index annualized 2.5%.
- **Sample and Bias Caveats** [00:56] — Sample covers Jan 2023–Aug 2026 (42 months) using current CSI 300 constituents, introducing survivorship bias. Short-window strength cannot be extrapolated as stable returns.
- **ABNR Construction** [01:08] — ABNR is constructed from daily open/close prices: separate intraday and overnight returns, flag days where overnight is up and intraday is down, compute monthly frequency, then standardize over past 12 months.
- **Data Sources** [01:52] — Original study used US stock database (May 1993–Dec 2017). This study uses domestic open-source data for CSI 300 current constituents, daily data from Jan 4, 2022 to Sep 3, 2026.
- **Long-Short Failure and Adjustments** [02:20] — Long-short rule nearly fails in CSI 300 long window. The tradable interpretation is revised to high-ABNR long-only. No modeling of price limits, suspensions, or impact costs.
- **Performance Comparison** [02:44] — Long-only clearly outperforms index; long-short weakens with deeper drawdowns. Short window (16 months) shows positive returns but too short for standalone conclusions.
- **Detailed Long-Window Results** [03:10] — Long window: cumulative 52.7%, annualized 12.9%, downside 0.80, max drawdown -12.7%. Index: cumulative 9.5%, annualized 2.5%, max drawdown -21.0%. Long-short cumulative -8.1%.
- **Short-Window Results** [03:36] — Short window (16 months): long-only cumulative 38.4%, annualized 27.6%, Sharpe 1.53. Strong but only for recent observation, not a substitute for long-window stability.
- **Costs and Implementation Details** [04:00] — Portfolio ~30 stocks equal-weight, month-end rebalance. Costs ~5bp per side deducted; no coverage of price limits, suspensions, impact, or execution deviation—real returns may be lower.
- **Signal Asymmetry** [04:12] — Only high-ABNR long works; short leg fails. Signal is asymmetric—use ABNR as a stock-selection and portfolio construction signal, not as a guaranteed mechanism.
- **Practical Usage** [04:29] — Use long window to decide whether to track the strategy; use short window to observe return decay. Don't add leverage based on 16-month 27.6% annualized.
- **Avoid Naive Shorting** [04:54] — Don't naively short the bottom decile in CSI 300; long-short cumulative -8.1% in long window, financing costs may worsen. Don't extrapolate current-constituent results to all A-shares.
- **Key Takeaway** [05:19] — ABNR can form a monthly equal-weight executable stock-selection process. Long-window cumulative 52.7%, annualized 12.9%, downside 0.80, better than index's 2.5%—a candidate for portfolio enhancement.
- **Final Recommendations** [05:31] — Don't copy US long-short results. Returns are strong but only 16 months; validate further. Before going live, incorporate survivorship bias, price limits, turnover impact, financing costs, and capacity.

### Conclusion

The ABNR long-only strategy on CSI 300 shows strong risk-adjusted returns (12.9% annualized vs 2.5% index), but the long-short version fails and the sample is short with survivorship bias. Use it as a candidate for portfolio enhancement, not a guaranteed edge.

## Transcript

本期附现一篇,隔夜日内反转研究,打开收盘价够高的ADNR信号落在沪深300上,长窗扣分年化收益12.9%,下谱0.80,本回测改成值多多,每月末买入ADNR最高10分位,并等权,持有至下月末,不搬每股市多空,样本仅覆盖2023年1月至2026年8月,且采用当前沪深300成分,存在存活偏差,短窗强势不能直接外推,为稳定收益。
5月把主结论先掏开 本回收的可交易主策略是 沪深300高ABN2多头 长窗扣费后累计52.7% 年化12.9%
下谱0.80 同期指数年化仅2.5% 每月末买入ABN2最高10分位 并等权持有至下月末 只做多不做空 长窗多空对照反而为负
量本只有2023年1月至2026年8月 并采用当前护身三改成分 因此存活偏差和短窗强势都不能直接外推为稳定收益 月度调仓
从每日前付全开盘价和收盘价开始拆除日内收益与隔夜收益 把隔夜上涨前日内下跌的样本记为复日间反转日 每月先算齐占比NR
但用过去12个月精致标准化得到ABNR需积累12个月历史月末按ABNR从低到高排成10组,买入最高10分位全部成分等权,持有至下月末,再换仓主策略多头,每次约扣单边5个基点LS对照,按两小腿约10BP扣减,不做空,最低10分位全部成分等权,持有至下月末,再换仓主策略多头,每次约扣单边5个基点LS对照,
地案两条腿约10BP扣减不做空最低十分位 原文基于美股股票数据库日开盘和收盘数据 样本从1993年5月到2017年12月
主组合强调本权高减低多空 本研究改用国内开源行情源的前赋 全入行情覆盖沪深三百当前成分 日行情从2022年1月4日到2026年9月3日
祖国窗口从2023年1月到2026年8月 因为ADNR需积累12个月历史信号 而言文多空规则 在沪深300长窗巨额接近失效
于是把可交易解读修正为高ADNR多头 为做实质加权 也尚未建模涨跌停 停牌跳过和冲击成本 因此存在存活偏差 自路地方长窗里
Long Night明显高于同期指数 而LS Night整体走弱且回撤更深控头腿在护身三板上脱泪明显转窗里allnetlf net虽都转正但转窗只有16个月不能单独作为订餐依据
途中回撤也提醒高ABNR多头并非无回撤策略 长窗最大回撤仍达到-12.7% 因此不能把原研究的美股多空差 直接清理为A股交易预期
自扣费主结果呈现的很清楚 短量本42个月里高ABNR 多头的累计为52.7% 年化12.9% 下谱0.80
最大回撤-12.7% 同期指数累计只有9.5% 年化2.5% 最大回撤却达-21.0% 长窗多空对照累计-8.1%
下谱接近0 不适合作为默认识盘规则 短量本16个月里多头累计 38.4% 年化27.6% 夏普1.53% 虽强力长仓
但只能作为近况观察 不能替代长仓稳定性检验 不强势力机制 需要分开看 组合约30只股票等权 持有并用月末换仓 表内All in it
已按约单边5GP扣除减化成本 单位覆盖涨跌停 停跑开膨速进冲击 和实际成交偏离 实盘收益可能更低 安窗只有高ADNR多头有效
多空腿失效 信号可用部分主要集中在多头端同时ADPR多空并未稳定若与ABNR原有方向不对称解释尚未稳定验证因此本研究只把ABNR当作选股和组合构建信号
不把机制故事视作以正式的收益保证 若是幽默计算 ABNR并持有最高10分位等全头头 用长窗判断是否值得继续跟踪 用短窗观察收益是否衰减
但不能因缘16个月年化27.6% 下谷1.53 就单独加仓 做的是核对 成分调整 平台 涨跌停和月末成交10点 确认约5GP成本
假设是否现实 别做的是在沪深300上默认裸作空 最低时分位 拼多空 长窗累计 负8.1% 融券与采差成本可能更差 也不能把当前成分回撤外退到全A股
混用美股 多空差 当作本策略预期收益 其中可带走的结论是 用开盘价与收盘价度造ABNR 可以形成月平等权 可执行的粉股流程
长长扣费后累积52.7% 年化12.9% 下谱0.80% 优于同期沪深300的年化2.5% 资质跟踪的组合增强候选
不支持照搬美股市高低股多空转创 收益虽强但只有16个月 更适合继续外汇验证 落地前需把当前成分所获偏差 平台涨跌停 换手冲击
融资融券费用和实际容量 纳入交易检查资格